CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026

Rhea-AI Summary

CorMedix Therapeutics (Nasdaq: CRMD) will host an in-person and virtual Analyst Day in New York on February 10, 2026, from 1:00 PM to 3:00 PM Eastern.

The company will provide portfolio and pipeline updates, outline growth drivers and upcoming milestones, and feature KOLs and senior management discussing REZZAYO (Phase III) and DefenCath (Phase III).

News Market Reaction

+3.48%

7 alerts

+3.48% News Effect

+$22M Valuation Impact

$641M Market Cap

0.5x Rel. Volume

On the day this news was published, CRMD gained 3.48%, reflecting a moderate positive market reaction. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $22M to the company's valuation, bringing the market cap to $641M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Analyst day date: February 10, 2026 Event time: 1:00 PM–3:00 PM ET REZZAYO stage: Phase III +3 more

6 metrics

Analyst day date February 10, 2026 In-person and virtual analyst day in New York

Event time 1:00 PM–3:00 PM ET Duration of analyst day presentations and panels

REZZAYO stage Phase III Prophylaxis of fungal infections program

DefenCath stage Phase III Reduction of CLABSI in adult TPN patients

Current price $7.75 Price before analyst day announcement

52-week range $5.60–$17.43 CRMD 52-week low and high

Market Reality Check

Price: $7.76 Vol: Volume 1,902,886 is below...

low vol

$7.76 Last Close

Volume Volume 1,902,886 is below the 20-day average of 4,229,751 (relative volume 0.45). low

Technical Trading at $7.75, below the 200-day MA $11.32 and 55.54% under the 52-week high of $17.43.

Peers on Argus

CRMD traded flat while several biotech peers were down, including MRVI (-10%), U...

CRMD traded flat while several biotech peers were down, including MRVI (-10%), UPB (-6.37%), and QURE (-4.24%), pointing to stock-specific rather than sector-driven dynamics.

Historical Context

5 past events · Latest: Jan 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 09	Conference presentation	Positive	+1.6%	Planned corporate overview at the J.P. Morgan Healthcare Conference via webcast.
Jan 08	Leadership changes	Positive	-32.8%	CEO contract extension, new Chairman role, and hiring of a Chief Commercial Officer.
Jan 08	Preliminary earnings	Positive	-32.8%	Preliminary Q4/FY 2025 results with FY 2026 guidance and program timelines.
Dec 18	Clinical data update	Positive	+4.1%	Interim real‑world DefenCath data showing large reductions in CRBSI and hospitalizations.
Nov 12	Investment in peer	Neutral	+2.1%	Talphera Q3 update including a private placement first tranche led by CorMedix.

Pattern Detected

Recent history shows mixed alignment between news and price: positive clinical and corporate updates sometimes led to sharp declines, as on Jan 8, 2026, while other positive or neutral items produced modest gains.

Recent Company History

Over the past few months, CorMedix has reported preliminary Q4/FY 2025 results with substantial revenue and EBITDA guidance, highlighted positive real‑world DefenCath data in ~7,000 patients, and announced leadership and board changes emphasizing a diversified, cashflow‑positive profile. It also engaged investors via the J.P. Morgan Healthcare Conference and supported a Talphera private placement. Against this backdrop, the newly announced analyst day on Feb 10, 2026 extends an ongoing effort to showcase its commercial portfolio and late‑stage pipeline programs.

Regulatory & Risk Context

Active S-3 Shelf · $140,000

Shelf Active

Active S-3 Shelf Registration 2025-10-07

$140,000 registered capacity

An effective S-3ASR filed on 2025-10-07 registers up to 6,323,833 shares for resale by existing securityholders, including Deerfield funds. The company will receive no proceeds from these sales and disclosed $140,000 of related legal fees and expenses.

Market Pulse Summary

This announcement sets up an analyst day on February 10, 2026 to spotlight CorMedix’s portfolio and ...

Analysis

This announcement sets up an analyst day on February 10, 2026 to spotlight CorMedix’s portfolio and late‑stage programs, including Phase III studies for REZZAYO and DefenCath. It continues a pattern of active investor outreach following recent earnings, guidance, and clinical updates. Investors may focus on how management frames key growth drivers, upcoming milestones, and commercial opportunity, and how these messages compare with prior disclosures on revenue trends, pipeline timelines, and reimbursement dynamics.

Key Terms

phase iii, prophylaxis, total parenteral nutrition (tpn), clabsi

4 terms

phase iii medical

"REZZAYO ... program, in Phase III for the prophylaxis of fungal infections"

A Phase III trial is the late-stage clinical study that tests whether a medical treatment works and is safe in a large group of patients, often comparing it to standard care. Think of it as a final dress rehearsal or full-scale road test before regulators decide on approval; positive or negative results strongly influence a drug maker’s chance to sell the treatment, future revenue, and investment risk.

prophylaxis medical

"in Phase III for the prophylaxis of fungal infections"

Prophylaxis is a medical prevention strategy — a drug, vaccine, device, or procedure given to stop a disease or condition before it starts. For investors, prophylactic products matter because they can create steady, large markets and reduce long‑term healthcare costs; regulatory approval or broader adoption can change demand forecasts much like a new safety feature that becomes standard across an entire industry.

total parenteral nutrition (tpn) medical

"reduction of CLABSI in adult patients receiving Total Parenteral Nutrition (TPN)"

Total parenteral nutrition (TPN) is a medical treatment that delivers all essential nutrients—calories, protein, electrolytes, vitamins and fluids—directly into a patient’s bloodstream through a vein when they cannot eat or digest food. Investors care because TPN drives revenue and costs across hospitals, specialty pharmacies, device makers and drug suppliers; changes in patient demand, safety issues, regulatory rules or reimbursement can materially affect sales, margins and supply chains, similar to how fuel shipments matter to transportation companies.

clabsi medical

"DefenCath ... program, in Phase III for the reduction of CLABSI in adult patients"

A CLABSI is an infection that enters the bloodstream through a central line, a thin tube placed into a large vein to deliver medication or fluids. Like a contaminated pipe causing leaks in a building, these infections can lead to serious illness, longer hospital stays and higher treatment costs. For investors, CLABSIs matter because their incidence influences hospital expenses, reimbursement penalties, product demand and reputation risk across healthcare providers and device makers.

AI-generated analysis. Not financial advice.

BERKELEY HEIGHTS, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will host an in-person and virtual analyst day in New York on Tuesday, February 10, 2026 with presentations and panels from 1:00 PM to 3:00 PM Eastern. The Company will share background and updates across its portfolio and pipeline, and outline the business’ key growth drivers and upcoming milestones.

The event will feature key opinion leaders who will join members of the Company’s senior management team, offering insights into evolving market dynamics, areas of significant unmet medical need, and the commercial opportunity for CorMedix’s REZZAYO® (rezafungin for injection) program, in Phase III for the prophylaxis of fungal infections, and its DefenCath® (taurolidine and heparin) program, in Phase III for the reduction of CLABSI in adult patients receiving Total Parenteral Nutrition (TPN).

Presentations and panels will be followed by a live question-and-answer session hosted by management. Attendance in person is limited to analysts and institutional investors. To register for either the virtual webcast or the in-person event, please click here.

About CorMedix

CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. CorMedix is commercializing DefenCath® (taurolidine and heparin) for the prevention of catheter-related bloodstream infections in adult patients undergoing hemodialysis via a central venous catheter. Following its August 2025 acquisition of Melinta Therapeutics LLC, CorMedix is also commercializing a portfolio of anti-infective products, including MINOCIN® (minocycline) for Injection, REZZAYO® (rezafungin for injection), VABOMERE® (meropenem and vaborbactam), ORBACTIV™ (oritavancin), BAXDELA® (delafloxacin), and KIMYRSA® (oritavancin), as well as TOPROL-XL® (metoprolol succinate).

CorMedix has ongoing clinical studies for DefenCath in Total Parenteral Nutrition (TPN) and Pediatric Hemodialysis populations and also intends to develop DefenCath as a catheter lock solution for use in other patient populations. REZZAYO is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of IFD in adult patients undergoing allogeneic BMT. Topline results of the Phase III study for REZZAYO are expected in Q2 2026. For more information visit: www.cormedix.com or www.melinta.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Exchange, as amended (the “Exchange Act”), that are subject to risks and uncertainties. Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “will,” “plan,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions or variations intended to identify forward-looking statements. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or CorMedix’s prospects should be considered forward-looking statements including, but not limited to statements regarding financial guidance, sales, revenue and operating expense estimates, expectations regarding product utilization, product reimbursement rates, synergy estimates and timing, expectations and timing regarding clinical studies and development and expectations of CorMedix’s product pipeline, results of the real-world study, expectations regarding implementation and perceived benefits of CorMedix’s products. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, and readers are directed to the Risk Factors identified in CorMedix’s filings with the SEC, including its most recent Annual Report on Form 10-K, copies of which are available free of charge at the SEC’s website at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and such forward-looking statements speak only as of the date of this press release. Investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576

FAQ

When is CorMedix (CRMD) hosting its Analyst Day and what is the schedule on February 10, 2026?

The Analyst Day is on February 10, 2026, with presentations from 1:00 PM to 3:00 PM Eastern. According to the company, the program includes presentations, panels, and a live question-and-answer session with management and key opinion leaders.

How can investors register for CorMedix (CRMD) Analyst Day on February 10, 2026?

Investors can register for either the virtual webcast or limited in-person attendance via the company's registration links. According to the company, in-person attendance is restricted to analysts and institutional investors, while the webcast is open to registered virtual participants.

What topics will CorMedix (CRMD) cover at the February 10, 2026 Analyst Day?

CorMedix will cover portfolio and pipeline updates, growth drivers, and upcoming milestones. According to the company, sessions will include insights on market dynamics and the commercial opportunity for REZZAYO and DefenCath programs in Phase III.

Will CorMedix (CRMD) discuss REZZAYO and DefenCath development status at the February 10, 2026 event?

Yes, both REZZAYO and DefenCath will be discussed, noting they are in Phase III development. According to the company, panels will address clinical context, unmet need, and the commercial opportunity for each program.

Who will present at CorMedix (CRMD) Analyst Day on February 10, 2026 and what follows the presentations?

Presentations feature senior management and key opinion leaders, followed by a live question-and-answer session hosted by management. According to the company, panels will offer expert perspectives on clinical and commercial implications for the programs.